Sjögren’s syndrome

Primary Sjögren’s syndrome (pSS) is a common, systemic autoimmune disease that affects four million women in the United States. This disease is characterized by debilitating fatigue and lymphocytic infiltration of the salivary and lachrymal glands, leading to dry eyes and dry mouth. Currently, there are no approved therapies, and most treatments focus on relieving symptoms of dry eyes and mouth, and preventing long-term complications.

However, these approaches do not address many life altering symptoms, such as fatigue, which affects up to 70% of patients. Resolve is developing a novel treatment approach to more effectively address the underlying disease and meet the demonstrated unmet medical need.


Lupus is an autoimmune disease that affects five million people worldwide, and primarily impacts women. Lupus affects the joints, skin, brain, lungs, kidneys, and blood vessels, and can cause widespread inflammation and tissue damage. On average, it takes six years to accurately diagnosis lupus, since signs and symptoms often mimic other ailments. There are no cures for lupus and standard of care has not significantly improved in over 40 years. Current treatment relies on steroids and potent immunosuppressive agents, with limited efficacy and debilitating side effects. This serious unmet medical need is driving Resolve to develop a new, novel approach to reducing the impact of the debilitating symptoms of lupus.